Vaxart, Inc. Share Price

Equities

VXRT

US92243A2006

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 19/07/2024 BST 5-day change 1st Jan Change
0.675 USD -1.26% Intraday chart for Vaxart, Inc. +0.70% +17.84%
Sales 2024 * 24.99M 1.93B Sales 2025 * 31.77M 2.46B Capitalization 153M 11.86B
Net income 2024 * -98M -7.59B Net income 2025 * -112M -8.67B EV / Sales 2024 * 6.13 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 4.82 x
P/E ratio 2024 *
-1.22 x
P/E ratio 2025 *
-1.36 x
Employees 109
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.55%
More Fundamentals * Estimated data
Dynamic Chart
1 day-1.26%
1 week+0.70%
Current month+1.15%
1 month-6.11%
3 months-10.67%
6 months-9.08%
Current year+17.84%
More quotes
1 week
0.66
Extreme 0.66
0.75
1 month
0.61
Extreme 0.605
0.77
Current year
0.52
Extreme 0.52
1.54
1 year
0.52
Extreme 0.52
1.54
3 years
0.52
Extreme 0.52
10.33
5 years
0.25
Extreme 0.2543
24.90
10 years
0.25
Extreme 0.2543
24.90
More quotes
Managers TitleAgeSince
Founder 56 31/12/03
Director of Finance/CFO 37 18/12/22
Chairman 65 30/06/07
Members of the board TitleAgeSince
Director/Board Member 66 24/10/19
Director/Board Member 76 24/08/22
Chairman 65 30/06/07
More insiders
Date Price Change Volume
19/07/24 0.675 -1.26% 1,098,862
18/07/24 0.6836 -3.20% 1,558,028
17/07/24 0.7062 -3.30% 1,794,810
16/07/24 0.7303 +7.95% 2,737,422
15/07/24 0.6765 +0.92% 1,821,480

Delayed Quote Nasdaq, July 19, 2024 at 09:00 pm

More quotes
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.675 USD
Average target price
5.25 USD
Spread / Average Target
+677.78%
Consensus